Page 5 - Cancer Update Spring 2019 Vol. 8 Issue 1
P. 5
Additionally, our oncology program through the Baylor Scott & White Research Institute is investigating a number of exciting and highly novel immunotherapeutic strategies across multiple hematologic and solid tumors. Research successes seen in recent years using CAR-T and NK cells along with other cellular therapies are very promising. Our program is primed to be a standout immunotherapy center in the US—a destination for advanced immunotherapy oncology trials with an eye on the psychological, familial and spiritual support that patients and their loved ones need along their journey.
We’re putting these building blocks together, and adding to them, to be an even stronger cancer program for the patients and families we serve today and those we’ll serve in the future. I look forward to sharing more exciting news with you in coming issues as we expand our program.
Ronan Kelly, MD, MBA
Chief of Oncology, Baylor Scott & White Health - North Texas Director, Baylor Charles A. Sammons Cancer Center – Dallas
3
